Johnson & Johnson Form 4 insider transactions

Joaquin Duato, CEO and Chairman of the Board and a Director of Johnson & Johnson, sold 48,480 shares of common stock on August 5, 2026.

Elizabeth Forminard, EVP, Chief Legal Officer of Johnson & Johnson, sold 15,918 shares of common stock on August 6, 2026.

Vanessa Broadhurst, EVP, Global Corp Affairs of Johnson & Johnson, sold 23,054 shares of common stock on July 20, 2026 for $251.27 per share.

Johnson & Johnson EVP Kathryn Wengel exercised 10,000 stock options and subsequently sold the shares on June 11, 2026.

Johnson & Johnson Director Eugene A. Woods acquired 161.089 deferred share units as part of the company's director compensation plan.

Johnson & Johnson director Daniel E. Pinto acquired 134.241 deferred share units as part of the company's director fee plan.

Johnson & Johnson Director Marillyn A. Hewson acquired 214.786 deferred share units as part of the company's director compensation plan.

Johnson & Johnson executive John C. Reed reported transactions involving restricted stock units and common stock, including awards under the company's Long-Term Incentive Plan.

Johnson & Johnson director Eugene A. Woods was granted 975 deferred share units as part of the company's director compensation plan.

Johnson & Johnson Director Nadja West was granted 975 deferred share units as part of the company's director compensation plan.

Johnson & Johnson Director Mark Weinberger acquired 975 deferred share units as part of the company's director compensation plan.

Johnson & Johnson Director Daniel E. Pinto acquired 1,712 deferred share units as part of the company's director compensation plan.

Director John G. Morikis acquired 1,540 deferred share units as part of the Johnson & Johnson director compensation plan.

Johnson & Johnson Director Mark B. McClellan was granted 975 deferred share units as part of the company's director compensation plan.

Johnson & Johnson Director Hubert Joly was granted 975 deferred share units as part of the company's director compensation plan.

Johnson & Johnson Director Paula A. Johnson acquired 975 deferred share units as part of the company's director compensation plan.

Director Marillyn A. Hewson acquired 975 deferred share units as part of the Johnson & Johnson director compensation plan.

Director Jennifer A. Doudna acquired 975 deferred share units as part of the Johnson & Johnson director compensation plan.

Johnson & Johnson director Mary C. Beckerle acquired 975 deferred share units as part of the company's director compensation plan.

Johnson & Johnson Director Marillyn A. Hewson filed a Form 4 reporting both a previously unreported acquisition of Deferred Share Units from 2025 and a new acquisition from 2026.

Johnson & Johnson Director Daniel E. Pinto acquired 129.058 Deferred Share Units as part of his compensation plan, increasing his total beneficial ownership to 462.069 units.

Johnson & Johnson Director Eugene A. Woods acquired 154.869 Deferred Share Units as part of his compensation plan.

Timothy Schmid, EVP and WW Chair of MedTech at Johnson & Johnson, reported the sale of 1,322 shares of common stock.

Johnson & Johnson's EVP and CIO, James D. Swanson, reported exercising stock options and converting equity awards, followed by sales to cover taxes and realize gains, while also receiving new equity grants.

Johnson & Johnson's EVP, Chief TO and Risk Officer, Kathryn E. Wengel, reported significant equity compensation transactions, including RSU and PSU vesting and new option grants.

Johnson & Johnson's EVP, Chief HR Officer Kristen Mulholland, filed a Form 4 detailing the vesting of equity awards and related tax withholdings.

Johnson & Johnson's Executive VP and CFO, Joseph J. Wolk, reported a series of equity transactions including vesting of awards, tax-related dispositions, and option exercises and sales.

Johnson & Johnson's VP Corporate Controller, Robert J. Decker, reported multiple equity transactions including RSU and PSU conversions, tax withholdings, and new stock option grants.

A Johnson & Johnson executive exercised stock options and sold shares for liquidity and tax purposes, while also receiving new equity awards.

Johnson & Johnson's EVP, Chief Legal Officer, Elizabeth Forminard, reported the vesting of restricted and performance share units, along with the exercise of stock options and subsequent tax-related share dispositions.